Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
France
/
Pharmaceuticals & Biotech
/
Transgene
TNG
Transgene
High-Risk Clinical Trials And Rising Costs Will Delay Returns Yet Unlock Value
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
14 Aug 25
Updated
14 Aug 25
1
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
€1.40
26.4% undervalued
intrinsic discount
14 Aug
€1.03
Loading
1Y
1.0%
7D
1.5%
Author's Valuation
€1.4
26.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
€1.4
26.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-42m
18m
2014
2017
2020
2023
2025
2026
2028
Revenue €14.1m
Earnings €1.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
32.49%
Biotech revenue growth rate
12.78%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.98%
Calculation
€1.11m
Earnings '28
x
433.55x
PE Ratio '28
=
€483.09m
Market Cap '28
€483.09m
Market Cap '28
/
289.86m
No. shares '28
=
€1.67
Share Price '28
€1.67
Share Price '28
Discounted to 2025 @ 5.98% p.a.
=
€1.40
Fair Value '25
